Eckert & Ziegler stock slips 0.43% to EUR 13.95 pre-market
Published on 11/06/2026 at 08:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAc-225 milestone shapes focus
- Eckert & Ziegler Therapeutics received manufacturing authorization for Actinium-225 under Good Manufacturing Practice requirements.
- The production platform is intended to support clinical supply and future capacity expansion in Asia and North America.
Eckert & Ziegler stock is under pressure before the German market opens after the company highlighted a regulatory milestone for its Actinium-225 production platform.
The real-time quote of Eckert & Ziegler stock traded at EUR 13.95 on Lang & Schwarz at 08:41 CET on Friday, November 6, 2026, 0.43% below the Xetra close of Thursday, November 5, 2026 at EUR 14.01.
Production milestone supports supply plans
Eckert & Ziegler Therapeutics GmbH, a wholly owned subsidiary, received manufacturing authorization for Actinium-225 on November 3. The certification confirms that production meets Good Manufacturing Practice requirements and facilitates the use of the radioisotope in investigational patient treatments.
According to Cold Chain Platform, the production route combines irradiation at the Czech Academy of Sciences' Nuclear Physics Institute with processing at Eckert & Ziegler's Braunschweig site. The company also plans a production facility in China, while additional capacity near Boston and in Germany may support future commercial supply.
Investors will weigh the regulatory progress against execution risks in scaling production and developing clinical and commercial demand.
The broader European equity market will provide the backdrop as investors assess healthcare and industrial shares; see current Euro Stoxx 50 market coverage.
